Literature DB >> 1717151

Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma.

K N Khan1, K Nakata, Y Kusumoto, M Shima, N Ishii, T Koji, S Nagataki.   

Abstract

The serial changes in serum hepatic enzyme activities by transcatheter arterial embolization (TAE) were analyzed in 17 patients with hepatocellular carcinoma to estimate the contribution to the value by the damage of tumor or nontumorous hepatic cells. The serum levels of relatively tumor-specific fructose 1,6-diphosphate (FDP) aldolase were elevated after TAE in the cases of both superselective and nonsuperselective TAE that were performed from the segmental and the nonsegmental hepatic artery, respectively, but we found the marked elevation of FDP aldolase in the cases of the superselective TAE. In contrast, the non-tumor-specific fructose 1-phosphate (F1P) aldolase was markedly elevated only in the cases of nonsuperselective TAE. The total amount of FDP aldolase released by TAE correlated significantly with the integrated tumor tissue volume (P less than 0.005), whereas the total amount of F1P aldolase output correlated significantly with the integrated nontumorous tissue volume (P less than 0.005) as defined by lipiodol accumulation on computerized tomography scan. The consequent changes in the total nontumorous liver volumes after TAE were also analyzed by the follow-up computerized tomography scan. The nonsuperselective TAE caused the significant total nontumorous liver atrophy when compared with the superselective TAE. The progression of the total nontumorous liver atrophy correlated significantly with F1P aldolase output by TAE (P less than 0.001) but not with FDP aldolase output. These results suggest that the outputs of FDP and F1P aldolase are useful to estimate the degree of the tumorous and nontumorous tissue damage by TAE, respectively, and F1P aldolase output can be used to predict the progression of liver atrophy caused by TAE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717151

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Ethanol injection for the treatment of hepatic tumours.

Authors:  C Bartolozzi; R Lencioni
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 2.  Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice.

Authors:  Shuangxi Li; Xuewen He; Lei Dang; Fangyu Xu; Jin Fang; Fenqiang Li; Wenhui Wang
Journal:  Dig Dis Sci       Date:  2018-01-05       Impact factor: 3.199

3.  Hepatic perfusion changes after transcatheter arterial embolization (TAE) of hepatocellular carcinoma: measurement by dynamic computed tomography (CT).

Authors:  Y Tsushima; Y Unno; J Koizumi; S Kusano
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation.

Authors:  Y Yamashita; M Torashima; T Oguni; A Yamamoto; M Harada; T Miyazaki; M Takahashi
Journal:  Abdom Imaging       Date:  1993

5.  Use of FDP and F1P aldolase to detect tumorous and nontumorous tissue damage by ethanol injection of hepatocellular carcinoma.

Authors:  K N Khan; K Nakata; K Nakao; Y Kato; K Eguchi
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

6.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

7.  Segmental transcatheter arterial embolization for primary hepatocellular carcinoma.

Authors:  Li Li; Pei-Hong Wu; Jin-Qing Li; Wei-Zhang Zhang; Hao-Gao Lin; Ya-Qi Zhang
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

8.  Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea.

Authors:  Yon Mi Sung; Dongil Choi; Hyo K Lim; Won Jae Lee; Seung Hoon Kim; Min Ju Kim; Seung Woon Paik; Byung Chul Yoo; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi
Journal:  Korean J Radiol       Date:  2006 Jul-Sep       Impact factor: 3.500

9.  Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.

Authors:  Rodolfo Sacco; Marco Bertini; Pasquale Petruzzi; Michele Bertoni; Irene Bargellini; Giampaolo Bresci; Graziana Federici; Luigi Gambardella; Salvatore Metrangolo; Giuseppe Parisi; Antonio Romano; Antonio Scaramuzzino; Emanuele Tumino; Alessandro Silvestri; Emanuele Altomare; Claudio Vignali; Alfonso Capria
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

10.  Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Noboru Maeda; Keigo Osuga; Koji Mikami; Hiroki Higashihara; Hiromitsu Onishi; Yasuhiro Nakaya; Mitsuaki Tatsumi; Masatoshi Hori; Tonsok Kim; Kaname Tomoda; Hironobu Nakamura
Journal:  Radiat Med       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.